STOCK TITAN

FDMT (NASDAQ: FDMT) CLO sells 6,566 shares, exercises options under 10b5-1 plan

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

4D Molecular Therapeutics Chief Legal Officer Scott Bizily reported an option exercise-and-sale transaction in company stock. On June 30, 2026, he sold 6,566 shares of common stock at $14.00 per share in an open-market transaction made pursuant to a Rule 10b5-1 trading plan adopted on January 13, 2026.

On the same date, he exercised stock options covering 5,752 shares at an exercise price of $6.49 per share and 814 shares at $4.14 per share, converting these derivative awards into common shares. The options exercised were from grants originally scheduled to vest monthly over four years and carried expiration dates in 2032 and 2035.

Positive

  • None.

Negative

  • None.
Insider Bizily Scott
Role Chief Legal Officer
Sold 6,566 shs ($92K)
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) 814 $0.00 --
Exercise Stock Option (Right to Buy) 5,752 $0.00 --
Exercise Common Stock 814 $4.14 $3K
Exercise Common Stock 5,752 $6.49 $37K
Sale Common Stock 6,566 $14.00 $92K
Holdings After Transaction: Stock Option (Right to Buy) — 62,971 shares (Direct, null); Common Stock — 9,431 shares (Direct, null)
Footnotes (1)
  1. Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 13, 2026. The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of June 16, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.
Shares sold 6,566 shares Common stock sold on June 30, 2026
Sale price $14.00 per share Open-market sale of 6,566 common shares
Options exercised (grant 1) 5,752 shares at $6.49 Stock options exercised into common stock
Options exercised (grant 2) 814 shares at $4.14 Stock options exercised into common stock
10b5-1 plan adoption January 13, 2026 Plan governing June 30, 2026 open-market sale
Option expiration (grant 1) June 17, 2032 Expiration date for $6.49 strike options
Option expiration (grant 2) March 5, 2035 Expiration date for $4.14 strike options
Rule 10b5-1 trading plan regulatory
"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 13, 2026."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)" with underlying security title Common Stock."
derivative security financial
"transaction_code_description: "Exercise or conversion of derivative security" for the option exercises."
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
Vesting Commencement Date financial
"on each monthly anniversary of March 6, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested"
The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.
open-market sale financial
"transaction_action: "open-market sale" for 6,566 common shares at $14.00 per share."
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Bizily Scott

(Last)(First)(Middle)
C/O 4D MOLECULAR THERAPEUTICS, INC.
5858 HORTON STREET #455

(Street)
EMERYVILLE CALIFORNIA 94608

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
4D Molecular Therapeutics, Inc. [ FDMT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Legal Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/30/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/30/2026M814A$4.149,431D
Common Stock06/30/2026M5,752A$6.4915,183D
Common Stock06/30/2026S(1)6,566D$148,617D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$4.1406/30/2026M814 (2)03/05/2035Common Stock814$062,971D
Stock Option (Right to Buy)$6.4906/30/2026M5,752 (3)06/17/2032Common Stock5,752$03,543D
Explanation of Responses:
1. Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 13, 2026.
2. The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.
3. The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of June 16, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.
/s/ Scott Bizily07/02/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

At what prices did Scott Bizily sell and exercise FDMT shares?

He sold 6,566 FDMT common shares at $14.00 each. He also exercised options for 5,752 shares at a $6.49 strike and 814 shares at a $4.14 strike, converting these options into common stock.

Was Scott Bizily’s FDMT stock sale under a Rule 10b5-1 plan?

Yes, the open-market sale of 6,566 FDMT shares was executed under a pre-arranged Rule 10b5-1 trading plan adopted on January 13, 2026. Such plans automate trades, reducing the significance of trade timing decisions.

What type of options did Scott Bizily exercise in this FDMT Form 4?

He exercised stock options (Right to Buy) for 5,752 underlying FDMT shares at a $6.49 exercise price and 814 shares at a $4.14 exercise price, converting these derivative awards into common stock on June 30, 2026.

How many FDMT shares were involved in Scott Bizily’s June 30, 2026 transactions?

In total, 6,566 FDMT common shares were sold, and options for 6,566 underlying shares were exercised. The exercised options came from grants originally vesting monthly over four years, linked to 2022 and 2025 vesting commencement dates.

When do the FDMT stock options exercised by Scott Bizily expire?

The exercised options originated from grants with expiration dates in 2032 and 2035. Specifically, one grant expires on June 17, 2032, and another on March 5, 2035, reflecting long-dated equity awards tied to prior service.